RT Journal Article
SR Electronic
T1 Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2093
OP 2100
DO 10.21873/anticanres.14980
VO 41
IS 4
A1 TOZUKA, TAKEHIRO
A1 YANAGITANI, NORIKO
A1 YOSHIDA, HIROSHI
A1 MANABE, RYO
A1 OGUSU, SHINSUKE
A1 TSUGITOMI, RYOSUKE
A1 SAKAMOTO, HIROAKI
A1 AMINO, YOSHIAKI
A1 ARIYASU, RYO
A1 UCHIBORI, KEN
A1 KITAZONO, SATORU
A1 SEIKE, MASAHIRO
A1 GEMMA, AKIHIKO
A1 NISHIO, MAKOTO
YR 2021
UL http://ar.iiarjournals.org/content/41/4/2093.abstract
AB Background/Aim: The Renin–Angiotensin system (RAS) induces immunosuppression in the tumor microenvironment, and RAS inhibitors (RASi) improve the tumor immune microenvironment. We evaluated the impact of RASi on the efficacy anti-programmed cell death-1/Ligand-1 (anti-PD-1/PD-L1) antibodies. Patients and Methods: This retrospective study analyzed non-small cell lung cancer (NSCLC) patients who received anti-PD-1/PD-L1 antibodies monotherapy as second- or later-line treatment. We classified patients into those with or without use of RASi. Results: A total of 256 NSCLC patients were included and 37 patients used RASi. The median PFS of patients treated with RASi was significantly longer than that of patients treated without (HR=0.59, 95%CI=0.40-0.88). The median OS of patients treated with RASi tended to be longer than that of patients treated without (HR=0.71, 95%CI=0.45-1.11). Conclusion: The use of RASi was associated with a significantly longer PFS in NSCLC patients treated with anti-PD-1/PD-L1 antibodies. RASi use may enhance the efficacy of anti-PD-1/PD-L1 antibodies.